WO2023118294 - INHIBITION OF MITOFERRIN 2 AS MEANS FOR INHIBITING CANCER AND CANCER METASTASIS
National phase entry is expected:
Publication Number
WO/2023/118294
Publication Date
29.06.2023
International Application No.
PCT/EP2022/087235
International Filing Date
21.12.2022
Title **
[English]
INHIBITION OF MITOFERRIN 2 AS MEANS FOR INHIBITING CANCER AND CANCER METASTASIS
[French]
INHIBITION DE LA MITOFERRINE 2 EN TANT QUE MOYEN D'INHIBITION DU CANCER ET DE MÉTASTASES CANCÉREUSES
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
KATHOLIEKE UNIVERSITEIT LEUVEN
K.U.LEUVEN R&D Waaistraat 6 - bus 5105
3000 Leuven, BE
Inventors
FENDT, Sarah-Maria
Andreas Vesaliusstraat 69
3000 Leuven, BE
CUADROS, Alejandro
Diestsestraat 226 Bus 0201
3000 Leuven, BE
Priority Data
21216949.4
22.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1041 | |
| EPO | Filing, Examination | 4805 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9722 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to inhibition of mitoferrin 2 as a means for treating cancer, for preventing or inhibiting cancer metastasis, and for treating established metastases.[French]
L'invention concerne l'inhibition de la mitoferrine 2 en tant que moyen de traitement du cancer, pour la prévention ou l'inhibition de métastases cancéreuses, et pour le traitement de métastases établies.